All In Biotech

Drug Trial Radar · NCT06810882

Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy

Intravenous Versus Perineural Ondansetron as an Adjuvant in Autonomic Neural Blockade for Laparoscopic Sleeve Gastrectomy: A Two-Center, Randomized, Double-Blind, Non-inferiority Trial

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 482 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

482

Planned (sponsor's estimate)

Start

Feb 16, 2025

Primary completion

Feb 16, 2027

Study completion Feb 17, 2027

Sponsor

Lead sponsor
Tanta UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective randomized non-inferiority study will be conducted to compare the analgesic anti-emetic effects of intravenous ondansetron versus perineural ondansetron in patients undergoing laparoscopic sleeve gastrectomy.

Conditions

  • Ondansetron
  • Laparoscopic
  • Gastrectomy

Interventions

  • Perineural ondansetronDrug

    Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml (4 mg) ondansetron. At the same time, 15 ml saline will be injected slowly IV over 15 minutes.

  • Intravenous ondansetronDrug

    Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml saline. At the same time, 4 mg (2 ml) ondansetron mixed with 13 ml saline (total 15 ml) will be slowly injected IV over 15 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of vomiting in the early 8 hours after surgery.Time frame: 8 hours after surgery.
  2. Degree of postoperative pain at 1 hour after surgery as measured by the numerical rating scale pain score.Time frame: 1 hour after surgery.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tanta University Hospitals

    Tanta, Gharbia Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.